![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, April 15, 2016 10:18:08 AM
Quite the impressive Bio, chock full of success!
Best to all Longs. Enjoy! dp
http://www.bloomberg.com/research/stocks/people/person.asp?personId=1515869&privcapId=332954
Dr. Paul A. Friedman, M.D., is a Partner of Vilicus Ventures, LLC. Dr. Friedman is also a Cardiologist and Professor at Mayo Clinic. He is also a Professor of Medicine and a consultant of cardiovascular electrophysiology. He has more than 20 years of experience in the pharmaceutical industry. He served as the Chief Executive Officer of Incyte Corporation from November 2001 to January 13, 2014 and also as its President from May 2004 to January 13, 2014. From 1998 to October 2001, Dr. Friedman served as the President of DuPont Pharmaceuticals Research Laboratories. From 1994 to 1998, he served as President of Research and Development of The DuPont Merck Pharmaceutical Company. From 1991 to 1994, he served as Senior Vice President at Merck Sharp & Dohme Research Laboratories (Merck Research Laboratories). From 1985 to 1991, he held several executive positions there. From 1974 to 1985, Dr. Friedman served as an Associate Professor of Medicine and Pharmacology at Harvard Medical School. He has been Executive Chairman of Cerulean Pharma Inc. since October 29, 2014. Dr. Friedman has been Director of Synta Pharmaceuticals Corp since March 2014. He has been a Director of Cerulean Pharma Inc. since January 2014 and Durata Therapeutics, Inc. since May 16, 2013. He is the Vice Chair of Academic Affairs and Faculty Development at the Mayo Clinic. He is the Vice Chair of the Division of Cardiovascular Medicine at the Mayo Clinic. He has been a Non Executive Director of Gliknik, Inc. since February 25, 2013. He has been an Independent Director of Navitor Pharmaceuticals, Inc. since June 2015. He has been a Director at Incyte Corporation since November 2001. He has been an Independent Director of Verastem, Inc. since May 2014. He served as a Director of Auxilium Pharmaceuticals Inc. from June 2010 to January 29, 2015. He served as a Director of Sirtris Pharmaceuticals, Inc. from March 2008 to June 2008. He served as a Director of Bausch & Lomb Incorporated from June 2004 to October 2007. He is a Diplomate of the American Board of Internal Medicine. He is also the author of over 100 scientific publications. He has over 40 biomedical patents and has authored over 300 scientific publications, including books, book chapters, and original articles. He is the reviewer or editor of over 15 influential medical journals, and directs national and international medical education meetings. He has been the principal investigator of large, international, multicenter trials. He has also been the recipient of federal and regional research awards to assess and develop new healthcare technologies. Dr. Friedman received an M.D. Degree from Harvard Medical School in 1969 and Stanford University in California and an A.B. degree in Biology from Princeton University, Princeton, New Jersey, in 1964. He holds a Bachelor’s of Science in Electrical Engineering from the University of Texas and an Honors liberal Arts Degree (Plan II), also from the University of Texas.
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM